NICE Recommends Novartis' Tafinlar-Mekinist as Frontline Treatment for BRAF-Mutant NSCLC
The agency estimated that the drug combination's cost-effectiveness falls within what it considers an acceptable use of the NHS's resources.
AACR Studies Flag Molecular Differences in Colorectal Cancer Patients of African, European Ancestry
Data presented at the meeting underscored the importance of studying diverse populations in order to improve equity in precision oncology.
C4 Therapeutics Betting on Protein Degraders to Improve Responses to Precision Oncology Drugs
The company is focusing first on developing drugs against well-validated cancer driver proteins but has ambitions to go after undruggable targets.
Merck's Keytruda Plus Eisai's Lenvima Fail to Improve Survival in Two Phase III Trials
The trials were designed to evaluate the drug combination in certain patients with advanced melanoma and colorectal cancer.
FDA Accepts Pfizer sNDAs for Braftovi, Mektovi in BRAF V600E-Mutant NSCLC
The sNDA submissions include data from the Phase II PHAROS trial, results from which researchers will present at an upcoming medical meeting.